The Nitrosamine “Saga”: Lessons Learned from Five Years of ScrutinyRaphael Nudelman, Anne-Laure Werner, Grace Kocks et al.|Organic Process Research & Development|2023Cited by 78
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesDavid J. Ponting, Robert Thomas, Susanne Glowienke et al.|Regulatory Toxicology and Pharmacology|2024Cited by 13
Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines – a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limitsSusan P. Felter, Joel P. Bercu, Ashley M Mudd et al.|Regulatory Toxicology and Pharmacology|2025Cited by 5
Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity dataRobert A. Jolly, Raechel Puglisi, Alejandra Trejo-Martin et al.|Regulatory Toxicology and Pharmacology|2026Cited by 3
Industrial Genotoxicology Group: 36th Annual Meeting ReportDarren Kidd, Amy Wilson, Ian Crooks et al.|Mutagenesis|2024Cited by 0